Merck & Co (NYSE:MRK) was downgraded by equities research analysts at Jefferies Group from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, AR Network reports.
MRK has been the subject of a number of other recent research reports. Analysts at Credit Suisse initiated coverage on shares of Merck & Co in a research note to investors on Tuesday. They set a “neutral” rating and a $49.00 price target on the stock. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Tuesday. Finally, analysts at Argus raised their price target on shares of Merck & Co from $52.00 to $54.00 in a research note to investors on Friday, October 4th. They now have a “buy” rating on the stock. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $51.03.
Merck & Co (NYSE:MRK) opened at 47.49 on Friday. Merck & Co has a one year low of $40.02 and a one year high of $50.16. The stock has a 50-day moving average of $47.77 and a 200-day moving average of $47.27. The company has a market cap of $139.0 billion and a price-to-earnings ratio of 28.44.
Merck & Co (NYSE:MRK) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $0.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.02. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $11.22 billion. During the same quarter in the previous year, the company posted $1.05 earnings per share. The company’s revenue for the quarter was down 10.6% on a year-over-year basis. On average, analysts predict that Merck & Co will post $3.48 earnings per share for the current fiscal year.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.